SARS-COV2

Investigational

Approval Year

Substance Class	Structurally Diverse Created by `admin` on `Sat Dec 16 15:39:07 UTC 2023` Edited by `admin` on `Sat Dec 16 15:39:07 UTC 2023`
Source Materials Class	ORGANISM
Source Materials Type	VIRUS
Source Materials State	LIVE
Organism Family	Coronaviridae
Organism Genus	Betacoronavirus
Organism Species	severe acute respiratory syndrome-related coronavirus
Author	NONE
Infraspecific Type	STRAIN
Infraspecific Name	SARS-CoV-2
Part	WHOLE
Record UNII	B6L4N5Z4GH
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SARS-COV2

Common Name

English

COVID-19

Common Name

English

SARS-COV-2

Common Name

English

2019-NCOV

Common Name

English

SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (2019)

Common Name

English

Code System Code Type Description

FDA UNII

B6L4N5Z4GH

Created by admin on Sat Dec 16 15:39:09 UTC 2023 , Edited by admin on Sat Dec 16 15:39:09 UTC 2023

PRIMARY

Related Record Type Details


					1KUR4BN70F

CILGAVIMAB

INHIBITOR->TARGET ORGANISM

Amount:


					I1679X069H

BRILACIDIN

INHIBITOR->TARGET ORGANISM

Amount:


					QU5NBP9XL3

CORONAVAC ANTIGEN ADJUVATED WITH ALUM

VACCINE ANTIGEN->TARGET ORGANISM

Comments:

On February 5, 2021 Sinovac announced data from a 12,396-participant, Phase III trial in Brazil and Turkey showing CoronaVac to be 100% effective in preventing death or hospitalization in patients with COVID-19, 83.7% effective in avoiding cases that required any medical treatment, but just 50.65% effective at preventing infection with the virus.

Qualification:

EFFICACY

Amount:


					P45RTW33K4

Timcevibart

INHIBITOR->TARGET ORGANISM

Amount:


					N49R9D9AFB

CIGB-66

VACCINE ANTIGEN->TARGET

Amount:


					EW5GL2X7E0

FAVIPIRAVIR

INHIBITOR->TARGET ORGANISM

Comments:

DRUG APPROVED IN CHINA FOR COVID-19. Prodrug that InhibitS the RNA-dependent RNA polymerase after activation to triphosphate.

Amount:


					JS929A2LKC

Talovirtide

INHIBITOR->TARGET ORGANISM

Amount:


					49717AWG6K

RIBAVIRIN

INHIBITOR->TARGET ORGANISM

Comments:

A guanine derivative approved for treating HCV and respiratory syncytial virus (RSV) that has been evaluated in patients with SARS and MERS, but its side effects such as anaemia may be severe at high doses.

Amount:


					93M09WW4RU

UMIFENOVIR

INHIBITOR->TARGET ORGANISM

Amount:


					FA9G2YWR23

VIXICOVTOGENE OBOPLASMID

VACCINE ANTIGEN->TARGET ORGANISM

Amount:


					8VLF8J3FR3

Pitozinameran

GENE MODIFIED PROTEIN->TARGET ORGANISM

Amount:


					3QKI37EEHE

REMDESIVIR

INHIBITOR->TARGET ORGANISM

Comments:

In Vero E6 cells inhibits. Targets the RNA-dependent RNA polymerase and block viral RNA synthesis in a broad spectrum of RNA viruses, including human coronaviruses. A US patient with 2019-nCoV recovered after receiving intravenous remdesivir in January

Interaction Type:

BIOASSAY (CELLULAR)

Qualification:

EC50

Amount:


					83DC7W9PBC

Gorivitug

INHIBITOR->TARGET ORGANISM

Amount:


					054Q5D7VZI

ADINTREVIMAB

INHIBITOR->TARGET ORGANISM

Amount:


					PX665RAA3H

Ensitrelvir

INHIBITOR->TARGET ORGANISM

Amount:


					D474BW0A5E

ENUZOVIMAB

INHIBITOR->TARGET ORGANISM

Amount:


					M1QXB372B8

SARS-COV-2 CN2 STRAIN .BETA.-PROPIOLACTONE INACTIVATED VACCINE ANTIGEN

TARGET ORGANISM->VACCINE ANTIGEN

Comments:

AGAINST COVID DISEASE

Qualification:

EFFICACY

Amount:


					B6L4N5Z4GH

SARS-COV2

INHIBITOR->TARGET ORGANISM

Amount:


					28PLX9696B

Vecilmeran

VACCINE ANTIGEN->TARGET ORGANISM

Amount:


					775U4AS43Q

SPIKE GLYCOPROTEIN (SARS-COV-2) (339-347)

VACCINE ANTIGEN->TARGET ORGANISM

Amount:


					47LH5FC8FW

VR17-04

INHIBITOR->TARGET ORGANISM

Amount:


					8E88WSA6X3

UPANOVIMAB

INHIBITOR->TARGET ORGANISM

Interaction Type:

IN-VITRO

Amount:


					89K3MV8294

CX-037073

VACCINE ANTIGEN->TARGET ORGANISM

Amount:


					M1QXB372B8

SARS-COV-2 CN2 STRAIN .BETA.-PROPIOLACTONE INACTIVATED VACCINE ANTIGEN

VACCINE ANTIGEN->TARGET ORGANISM

Amount:


					45I6OFJ8QH

BAMLANIVIMAB

INHIBITOR->TARGET ORGANISM

Comments:

The antibody binds selectively to the spike protein of SARS-CoV-2.

Amount:


					20YWF2NH7O

47D11

INHIBITOR->TARGET ORGANISM

Amount:


					RBJ7D8ZH4X

Upalsecovatein

VACCINE ANTIGEN->TARGET ORGANISM

Amount:


					AP7FFK83RM

Ufrenmeran

VACCINE ANTIGEN->TARGET

Amount:


					B5S3K2V0G8

AZD-1222

VACCINE ANTIGEN->TARGET ORGANISM

Comments:

One dosing regimen (n=2,741) showed vaccine efficacy of 90% when AZD1222 was given as a half dose, followed by a full dose at least one month apart, and another dosing regimen (n=8,895) showed 62% efficacy when given as two full doses at least one month apart. The combined analysis from both dosing regimens (n=11,636) resulted in an average efficacy of 70%. no hospitalisations or severe cases of the disease were reported in participants receiving the vaccine. There were a total of 131 COVID-19 cases in the interim analysis

Qualification:

EFFICACY

Amount:


					5295LF55B6

Imelasomeran

INHIBITOR -> TARGET

Amount:


					QJ4WJD8DD3

INM-005

INHIBITOR->TARGET ORGANISM


					MF2PS6XPS4

VV116 free base

INHIBITOR->TARGET ORGANISM

Amount:


					2V3ZF46GMQ

Carocovatein

VACCINE ANTIGEN->TARGET ORGANISM

Amount:


					76JZE5DSN6

BBV-152 ANTIGEN

VACCINE ANTIGEN->TARGET

Amount:


					VF62JD6WN3

HUMAN ANTI-SARS-COV-2 IMMUNOGLOBULIN

INHIBITOR -> TARGET

Amount:


					6FH8H9CL41

PIDACMERAN

VACCINE ANTIGEN->TARGET ORGANISM

Amount:


					JVG3CC2YJ4

CVXGA1

VACCINE ANTIGEN->TARGET

Amount:


					SOA12P041N

NITAZOXANIDE

INHIBITOR->TARGET ORGANISM

Comments:

In Vero E6 cells

Qualification:

EC50

Amount:


					F2HTG1MH2D

RIAMILOVIR

INHIBITOR->TARGET ORGANISM

Amount:


					X86ZM6S3TQ

ABIMTRELVIR

INHIBITOR->TARGET ORGANISM

Amount:


					0FD207WKDU

CAMOSTAT

INHIBITOR->TARGET ORGANISM

Comments:

In vitro study showed that Camostat reduces significantly the infection of Calu-3 lung cells by SARS-CoV-2, the virus responsible for COVID-19.

Amount:


					Z4LZB5VCU4

RIMTERAVIMAB

INHIBITOR->TARGET ORGANISM

Amount:


					BD2KE88JH4

Zeldesmeran

VACCINE ANTIGEN->TARGET

Amount:


					GQ10EO148M

SARS-COV-2 WIV04 STRAIN .BETA.-PROPIOLACTONE INACTIVATED VACCINE ANTIGEN

VACCINE ANTIGEN->TARGET ORGANISM

Amount:


					YM6LN8TU2V

COVID-19 CONVALESCENT PLASMA

INHIBITOR -> TARGET

Amount:


					YU2RGF2APH

DVX-201

INHIBITOR->TARGET ORGANISM

Amount:


					977D2P9YYW

Sipavibart

INHIBITOR->TARGET ORGANISM

Amount:


					FN55K29HD1

SPIKE GLYCOPROTEIN (SARS-COV-2) (336-350)

VACCINE ANTIGEN->TARGET ORGANISM

Amount:


					N7Q9NLF11I

ETESEVIMAB

INHIBITOR->TARGET ORGANISM

Amount:


					09936A4QSN

SIMPINICLINE

INHIBITOR -> TARGET

Amount:


					VV9NW7QG2X

SARS-COV2 B.1.1.529 VARIANT

INFRASPECIFIC -> PARENT ORGANISM

Amount:


					N36VHK46PR

Raxtozinameran

VACCINE ANTIGEN->TARGET ORGANISM

Amount:


					64GK6D44AB

CX-036651

VACCINE ANTIGEN->TARGET ORGANISM

Amount:


					RGV27LC2Y8

RM-4848

INHIBITOR->TARGET ORGANISM

Amount:


					F0LZ415Z3B

TIXAGEVIMAB

INHIBITOR->TARGET ORGANISM

Amount:


					54HU9J47SF

Velucovacap

VACCINE ANTIGEN->TARGET ORGANISM

Amount:


					7R9A5P7H32

Nirmatrelvir

INHIBITOR->TARGET ORGANISM

Comments:

Differentiated normal human bronchial epithelial (dNHBE) cells

Qualification:

EC90

Amount:


					1MTK0BPN8V

SOTROVIMAB

INHIBITOR->TARGET ORGANISM

Amount:


					TJ5C56A5DW

R-AD5-S (RECOMBINANT ADENOVIRUS TYPE 5 CARRYING THE GENE FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) SPIKE GLYCOPROTEIN)

VACCINE ANTIGEN->TARGET ORGANISM

Amount:


					UI1U1MYH09

DARAPLADIB

INHIBITOR->TARGET ORGANISM

Amount:


					5C4T4W973X

Simaravibart

INHIBITOR->TARGET ORGANISM

Amount:


					5085ZFP6SJ

Tozinameran

VACCINE ANTIGEN->TARGET ORGANISM

Comments:

From 7 days after second dose to a median time of 2 months.

Qualification:

EFFICACY

Amount:


					5TP24STD1S

ZORECIMERAN

VACCINE ANTIGEN->TARGET ORGANISM

Amount:


					E749PN51FV

ORF1AB POLYPROTEIN (SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2)

PART/FRACTION -> PARENT ORGANISM

Amount:


					CC7MR4XE6T

Deunirmatrelvir

INHIBITOR->TARGET ORGANISM

Amount:


					4I9OVB1G7D

JNJ-5207852

INHIBITOR->TARGET ORGANISM

Amount:


					4QWG6N8QKH

HYDROXYCHLOROQUINE

INHIBITOR->TARGET ORGANISM

Comments:

after 24 hours incubation; works in cell culture may not work in-vivo

Qualification:

EC50

Amount:


					8JW4ZYR2CT

GENZ-123346

INHIBITOR->TARGET ORGANISM

Amount:


					JT2NS6183B

AD26.COV2.S

VACCINE ANTIGEN->TARGET ORGANISM

Amount:


					I0BGE6P6I6

REGDANVIMAB

INHIBITOR->TARGET ORGANISM

Amount:


					2AD5KH3SE4

AMUBARVIMAB

INHIBITOR->TARGET ORGANISM

Amount:


					4F9QRS7ZV2

Andusomeran

VACCINE ANTIGEN->TARGET ORGANISM

Amount:


					SM01RRU9KK

ROMLUSEVIMAB

INHIBITOR->TARGET ORGANISM

Amount:


					GZH7FFK82R

SAB-185

INHIBITOR->TARGET ORGANISM

Amount:


					JV8KBX6XZG

ABDAVOMERAN

VACCINE ANTIGEN->TARGET ORGANISM

Amount:


					1BQK176DT6

GS-441524

INHIBITOR->TARGET ORGANISM

Amount:


					XJ51YOB1SC

LUFOTRELVIR

INHIBITOR->TARGET ORGANISM

Amount:


					J9E7RSF8K3

Zapomeran

VACCINE ANTIGEN->TARGET

Amount:


					5C2EJ8H89M

PF-07329268

INHIBITOR->TARGET ORGANISM

Comments:

Epithelial Vero E6 cells; EC50 Nirmatrelvir = 74.5

Amount:


					EPK39PL4R4

ELASOMERAN

VACCINE ANTIGEN->TARGET ORGANISM

Amount:


					J0FI6WE1QN

CASIRIVIMAB

INHIBITOR->TARGET ORGANISM

Amount:


					LG5UQ83MXK

CX-039300

VACCINE ANTIGEN->TARGET ORGANISM

Amount:


					6ZH4JN5VVR

MASAVIBART

INHIBITOR->TARGET ORGANISM

Amount:


					OLF97F86A7

GALIDESIVIR

INHIBITOR->TARGET ORGANISM

Comments:

Has shown antiviral activities in preclinical studies against many RNA viruses, including SARS and MERS.

Amount:


					C3JH443FGL

R-AD26-S (RECOMBINANT ADENOVIRUS TYPE 26 CARRYING THE GENE FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) SPIKE GLYCOPROTEIN)

VACCINE ANTIGEN->TARGET ORGANISM

Amount:


					Y25LQ0H97D

NAFAMOSTAT

INHIBITOR->TARGET ORGANISM

Amount:


					C3D11PV2O4

N4-HYDROXYCYTIDINE

INHIBITOR->TARGET ORGANISM

Amount:


					8JTY7VW9J8

Tegrenmeran

VACCINE ANTIGEN->TARGET ORGANISM

Amount:


					PV6AA88RDU

ENSOVIBEP

INHIBITOR->TARGET ORGANISM

Amount:


					UK9AK2IN1P

NVX-COV2373

VACCINE ANTIGEN->TARGET ORGANISM

Amount:


					I74C16KK3J

GANULAMERAN

VACCINE ANTIGEN->TARGET ORGANISM

Amount:


					886U3H6UFF

CHLOROQUINE

INHIBITOR->TARGET ORGANISM

Comments:

In Vero E6 cells

Qualification:

EC50

Amount:


					YA84KI1VEW

MOLNUPIRAVIR

INHIBITOR->TARGET ORGANISM

Amount:


					2G8MNM5LHS

NEPUVIBART

INHIBITOR->TARGET ORGANISM

Amount:


					JSV288Q5CV

Famtozinameran

VACCINE ANTIGEN->TARGET ORGANISM

Amount:


					5AHC3V2UQS

AD5-NCOV

VACCINE ANTIGEN->TARGET ORGANISM

Amount:


					83BU3492RP

GS-621763

INHIBITOR->TARGET ORGANISM

Amount:


					3E9P89C6JX

Vintesomeran

VACCINE ANTIGEN->TARGET ORGANISM

Amount:


					12U14K0SR5

PLUTAVIMAB

INHIBITOR->TARGET ORGANISM

Interaction Type:

IN-VITRO

Amount:


					RGE5K1Q5QW

RUPINTRIVIR

INHIBITOR->TARGET ORGANISM

Amount: